Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.36 |
| ▸ | SARS1 | P49591 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582239 | 0.92 | CDK5 (0.38) | ADORA2AADORA3ADORA1 | |
| SCHEMBL6362480 | 0.87 | ADORA2A (0.37) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL7197488 | 0.87 | ADORA2A (0.37) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL1582124 | 0.84 | HINT1 (0.39) | ADORA2AADORA3STING1 | |
| SCHEMBL27419759 | 0.79 | ADORA2A (0.36) | ADORA2AADORA3ADORA1STING1SARS1 | |
| SCHEMBL6402479 | 0.73 | STING1 (0.49) | ADORA3STING1 | |
| SCHEMBL20547879 | 0.72 | STING1 (0.35) | STING1 | |
| SCHEMBL22559797 | 0.72 | ADORA2A (0.34) | ADORA2AADORA3ADORA1SARS1 | |
| SCHEMBL16392689 | 0.72 | ADORA2A (0.34) | ADORA2AADORA3ADORA1SARS1 | |
| SCHEMBL8939101 | 0.72 | STING1 (0.38) | ADORA2AADORA3STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | SIRNA THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6686463-B2 | FEWER SYNTHETIC STEPS; INVOLVES FORMATION OF A 5',4'-BRIDGING SILYL PROTECTING GROUP TO FORM A FUSED SILOXANE ON THE FURAN RING | SIRNA THERAPEUTICS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | disclosed |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | RIBOZYME PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059817-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA2A 287/4885ADORA3 516/4885ADORA1 652/4885 |
| US-20020120129-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA2A 278/4885ADORA3 636/4885ADORA1 826/4885 |
| US-20020150936-A1 | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives | PNP, NSUN2, NT5C3B | ADORA2A 310/4885ADORA3 645/4885ADORA1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.